1-5 of 5
Wei-Ting Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

A. Gregory Sorensen, Tracy T. Batchelor, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Y. Wen, Johanna Lahdenranta, Marek Ancukiewicz, Emmanuelle di Tomaso, Dan G. Duda, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5296–5300.
https://doi.org/10.1158/0008-5472.CAN-09-0814
Published: 01 July 2009
View article titled, A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Open the PDF for A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study

A. Gregory Sorensen, Tracy Batchelor, Marek Ancukiewicz, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Wen, Johanna Lahdenranta, Emmanuelle di Tomaso, Dan Duda, Rakesh Jain
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): LB-94.
Published: 01 May 2009
View article titled, Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study
Journal Articles

Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Tracy T Batchelor, Gregory Sorensen, Emmanuelle di Tomaso, Dan G Duda, Wei-Ting Zhang, Marek Ancukiewicz, Johanna Lahdenranta, David Louis, Scott Plotkin, Percy Ivy, Jay S Loeffler, Patrick Wen, Rakesh K Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-247.
https://doi.org/10.1158/1538-7445.AM2008-LB-247
Published: 15 May 2008
View article titled, Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Journal Articles

A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Tracy Batchelor, Gregory Sorensen, Emmanuelle di Tomaso, Dan Duda, Wei-Ting Zhang, Marek Ancukiewicz, Johanna Lahdenranta, David Louis, Scott Plotkin, Percy Ivy, Jay Loeffler, Patrick Wen, Rakesh Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-247.
Published: 01 May 2008
View article titled, A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Journal Articles

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients

Tracy Batchelor, Dan Duda, Emmanuelle di Tomaso, Kevin Kozak, Wei-Ting Zhang, Marek Ancukiewicz, Jay Loeffler, Patrick Wen, Gregory Sorensen, Rakesh Jain
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 2118.
Published: 01 May 2007
View article titled, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients